U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.
Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P00734|||Q9UCA1
Gene ID: 2147.0
Gene Symbol: F2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ANGIOMAX

Approved Use

Angiomax™ is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Launch Date

2000
PubMed

PubMed

TitleDatePubMed
Thrombin-specific inhibition by and slow cleavage of hirulog-1.
1992 May 1
Direct thrombin inhibitors.
1999 Dec
Clinical outcomes of bivalirudin for ischemic heart disease.
1999 Nov 16
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.
2001 Dec
Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.
2001 Dec 1
Direct and indirect antithrombins. Heparins, low molecular weight heparins, heparinoids, and hirudin.
2001 Feb
Thrombin inhibitor approved for anticoagulation during angioplasty.
2001 Mar 1
Hirulog-like peptide reduces balloon catheter injury induced neointima formation in rat carotid artery without increase in bleeding tendency.
2001 Mar-Apr
Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi.
2001 May
Caspofungin acetate, bivalirudin.
2001 Oct 1
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction.
2002
Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
2002
Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
2002 Apr
Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
2002 Apr
Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
2002 Aug
Bivalirudin: a direct thrombin inhibitor for percutaneous transluminal coronary angioplasty.
2002 Aug
Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery.
2002 Dec
Current anticoagulation options in percutaneous intervention: designing patient-specific strategies.
2002 Fall
Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin.
2002 Feb
Publication policy, informed consent, and the randomized clinical trial.
2002 Feb
Reversing anticoagulants both old and new.
2002 Jun-Jul
Percutaneous coronary intervention with bivalirudin anticoagulation, immediate sheath removal, and early ambulation: a feasibility study with implications for day-stay procedures.
2002 Mar
Gateways to clinical trials.
2002 Oct
A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial.
2002 Oct 30
Heparin-induced thrombocytopenia: pathophysiology and new treatment options.
2002 Sep-Dec
Heparin-induced thrombocytopenia and cardiac surgery.
2003 Aug
Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
2003 Aug
Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?
2003 Aug
Clinician update: direct thrombin inhibitors in acute coronary syndromes.
2003 Feb
Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass.
2003 Feb
The evolving role of direct thrombin inhibitors in acute coronary syndromes.
2003 Feb 19
Should bivalirudin replace heparin during percutaneous coronary interventions?
2003 Feb 19
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
2003 Feb 19
Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass.
2003 Jan
Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia.
2003 Jan-Feb
Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits.
2003 Jul
Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention.
2003 Jul 15
Current anticoagulant therapy--unmet clinical needs.
2003 Jul 15
Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions.
2003 Jun
Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure.
2003 Mar
Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study.
2003 Mar 15
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
2003 Mar 15
Predicting the pharmacology of thrombin inhibitors.
2003 May
In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant.
2003 May
A 24-hour continuous infusion study of bivalirudin in the rat.
2003 May-Jun
Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention.
2003 Nov 1
Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia.
2003 Oct
Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where?
2003 Oct
Argatroban for off-pump coronary artery bypass surgery.
2003 Oct
Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin.
2004 Jan 15
Patents

Sample Use Guides

The recommended dosage of Angiomax (bivalirudin) is an intravenous (IV) bolus dose of 1.0 mg/kg followed by a 4-hour IV infusion at a rate of 2.5 mg/kg/h. After completion of the initial 4-hour infusion, an additional IV infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours if needed.
Route of Administration: Intravenous
Substance Class Protein
Created
by admin
on Wed Apr 02 08:41:11 GMT 2025
Edited
by admin
on Wed Apr 02 08:41:11 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
TN9BEX005G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIVALIRUDIN
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BG-8967
Preferred Name English
bivalirudin [INN]
Common Name English
BIVALIRUDIN [ORANGE BOOK]
Common Name English
BIVALIRUDIN [VANDF]
Common Name English
BIVALIRUDIN [MART.]
Common Name English
Bivalirudin [WHO-DD]
Common Name English
BIVALIRUDIN [EMA EPAR]
Common Name English
L-LEUCINE, D-PHENYLALANYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYLGLYCYLGLYCYLGLYCYL-L-ASPARAGINYLGLYCYL-L-.ALPHA.-ASPARTYL-L-PHENYLALANYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-PROLYL-L-.ALPHA.-GLUTAMYL-L-.ALPHA.-GLUTAMYL-L-TYROSYL-
Systematic Name English
BIVALIRUDIN [MI]
Common Name English
BIVALIRUDIN [USP-RS]
Common Name English
BG8967
Code English
BIVALIRUDIN [USAN]
Common Name English
Classification Tree Code System Code
WHO-ATC B01AE06
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
FDA ORPHAN DRUG 200204
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
NDF-RT N0000175980
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
NDF-RT N0000175518
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
NCI_THESAURUS C263
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
Code System Code Type Description
SMS_ID
100000085243
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
DAILYMED
TN9BEX005G
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
RS_ITEM_NUM
1076013
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
EVMPD
SUB05862MIG
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
DRUG CENTRAL
385
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
MERCK INDEX
m2581
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
DRUG BANK
DB00006
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
CAS
128270-60-0
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
USAN
FF-67
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
CHEBI
59173
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
NCI_THESAURUS
C47415
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
FDA UNII
TN9BEX005G
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
WIKIPEDIA
Bivalirudin
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID00155847
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
INN
7282
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
LACTMED
Bivalirudin
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
RXCUI
60819
Created by admin on Wed Apr 02 08:41:11 GMT 2025 , Edited by admin on Wed Apr 02 08:41:11 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC